ClinicalTrials.gg
RecruitingNCT02947971Updated Nov 10, 2026

Pilot Study for TCE Imaging of the Esophagus Using an OFDI Capsule With a Compact Imaging System

An interventional study of Experimental OFDI Imaging in Barrett's Esophagus, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 14 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Apr 2016; still recruiting 10 years 7 months later.
Updated Nov 10, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
14 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Barrett Esophagus by Massachusetts General Hospital — 3 open to participants now, 6 under way, none of them phase 3. Barrett Esophagus · Massachusetts General Hospital.

Planned enrollment
4th of 13
120 · median 50
Started
2016
with 1 other
No phase
13 of 17
3 open now
Registered
12th of 17
by date

Among the 17 studies in Barrett Esophagus by Massachusetts General Hospital, this one is the 4th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2016, is one of 13 with no phase, and was the 12th registered.

Barrett Esophagus

312 studies on the registry are indexed under Barrett Esophagus; 60 are open to participants now.

Browse Barrett Esophagus studies →

Open to participants now

3 of the 17 studies in Barrett Esophagus by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 44 Barrett Esophagus studies recruiting now, 31 (70%) set no upper age limit and 2 (5%) stop at 75 or younger; 4 take children under 18; 10 take healthy volunteers.

This study: 14 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Barrett Esophagus by Massachusetts General Hospital, or all of them as a file.
02

Study summary

The goal of this research is to test a distal scanning capsule and a compact redesigned version of the OFDI imaging system in healthy and BE participants to assess ease of use, safety and feasibility in preparation for its use in a multicenter clinical trial.

Read the detailed description

Thirty healthy participants, thirty participants with a previous diagnosis of Barrett's Esophagus (BE), thirty participants with a previous diagnosis of gastroesophageal reflux disease (GERD), and thirty volunteers with a previous diagnosis of eosinophilic esophagitis will be enrolled in the study.

The capsule is attached to a string-like tether which allows the operator to control as well as navigate the capsule as it progresses down the esophagus using peristalsis.

Images of the esophagus will be acquired in real time to be analyzed later.

03

Conditions studied

  • Barrett's Esophagus

Browse trials for

Keywords

  • Device
  • OFDI
  • Tethered Capsule Endomicroscopy
04

Who can participate

Ages eligible
14 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A previous diagnosis of BE (not an inclusion criteria for healthy volunteers)
  • Participants 18 years and older with a previous diagnosis of GERD
  • Participants 14 years and older with a previous diagnosis of EoE (not an inclusion criteria for healthy volunteers)
  • Health participants over the age of 18 but less than 85 years of age
  • Participants must be able to give
  • Participants must have no solid food for 4 hours prior to the procedure, and only clear liquids for 2 hours prior to the procedure.

Exclusion criteria

Exclusion Criteria:

  • Participants over 85 years of age
  • Participants with the inability to swallow pills and capsules.
  • Participants with a strong gag reflex
  • Esophageal fistula and/or esophageal strictures with a stricture diameter that is smaller than the diameter of the capsule.
  • Participants who are pregnant. In case of women of child bearing age, we will ask them if they are pregnant and if unsure; ask them to take a pregnancy test.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    OFDI Imaging

    Experimental OFDI Imaging

    Device: Experimental OFDI Imaging

Interventions

  • DeviceExperimental OFDI Imaging

    Imaging of the esophagus with a compact OFDI system and distal scanning catheter

06

What researchers measure

Primary outcomes

  1. Assessment of quality and performance of Compact Imaging System (CIS)

    Images obtained from the CIS will be assessed for quality and compared to images acquired from the previous imaging system

    Time frame: 5-7 Minutes of imaging

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2016 (actual). Primary completion is estimated for Dec 2028, 152 months after the start.

Of 65 non-industry interventional studies with no phase under Barrett Esophagus, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 108. This study's planned 152 months is above that.

Counting every sponsor, half of 76 studies reached it within 45 months; a quarter within 23 and three quarters within 108.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Dec 2026 → Dec 2028 and completion Dec 2028 → Dec 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2016
First posted
Oct 28, 2016
StartActual
Apr 15, 2016
Primary completionEst.
Dec 2028was Dec 2026
CompletionEst.
Dec 2030was Dec 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2026→Dec 2028
Nov 10, 2026
Study completion
Dec 2028→Dec 2030
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Primary completion Dec 2026→Dec 2028
    Study completion Dec 2028→Dec 2030
    + 3 other changes: verification date, oversight details and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02947971
Responsible party
Guillermo Tearney (Professor of Pathology, Massachusetts General Hospital) — Principal investigator
First posted
Oct 28, 2016
Start date
Apr 15, 2016
Primary completion
Dec 2028 (estimated)
Completion
Dec 2030 (estimated)
Last update
Nov 10, 2026

Study contacts

Juleen Guoy, RN
Contact
Tearneylabtrials@partners.org
617-726-5317
Anita Chung, RN
Contact
Tearneylabtrials@partners.org
617-724-4515
Guillermo Tearney, MD, PhD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion